Efficacy of a human anti-RANKL antibody (Denosumab) on prevention of steroid-induced osteoporosis in patients with autoimmune hepatitis (AIH)
Latest Information Update: 09 Jun 2016
At a glance
- Drugs Denosumab (Primary)
- Indications Corticosteroid-induced osteoporosis
- Focus Therapeutic Use
- 07 Jun 2016 Status changed from recruiting to active, no longer recruiting.
- 01 Jul 2014 New trial record